for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Merck & Co., Inc.

MRK

Latest Trade

78.29USD

Change

-0.40(-0.51%)

Volume

7,894,197

Today's Range

78.22

 - 

79.15

52 Week Range

71.72

 - 

87.80

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
78.69
Open
79.06
Volume
7,894,197
3M AVG Volume
260.97
Today's High
79.15
Today's Low
78.22
52 Week High
87.80
52 Week Low
71.72
Shares Out (MIL)
2,532.06
Market Cap (MIL)
198,234.80
Forward P/E
12.08
Dividend (Yield %)
3.32

Next Event

Merck & Co Inc Annual Shareholders Meeting

Latest Developments

More

Merck Announces Phase 3 KEYNOTE-522 Trial Met Dual Primary Endpoint

Merck Says Declared Special Dividend For Organon Spinoff

Merck And Eisai Receive Priority Review From FDA For Keytruda® (Pembrolizumab) Plus Lenvima® (Lenvatinib) Applications For Advanced Renal Cell Carcinoma And For Advanced Endometrial Carcinoma

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Merck & Co., Inc.

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices.

Industry

Biotechnology & Drugs

Contact Info

2000 Galloping Hill Rd

KENILWORTH, NJ

07033-1310

United States

+1.908.7404000

http://www.merck.com/

Executive Leadership

Kenneth C. Frazier

Chairman of the Board, Chief Executive Officer

Robert M. Davis

President

Caroline Litchfield

Chief Financial Officer, Executive Vice President

Franklin K. Clyburn

President, Human Health, Head of Human Health Commercial and Marketing

Dean Y. Li

President - Merck Research Laboratories

Key Stats

1.96 mean rating - 24 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

42.3K

2019

46.8K

2020

48.0K

2021(E)

52.0K
EPS (USD)

2018

4.340

2019

5.190

2020

5.940

2021(E)

6.481
Price To Earnings (TTM)
28.30
Price To Sales (TTM)
4.13
Price To Book (MRQ)
7.35
Price To Cash Flow (TTM)
18.38
Total Debt To Equity (MRQ)
115.99
LT Debt To Equity (MRQ)
89.08
Return on Investment (TTM)
11.21
Return on Equity (TTM)
8.02

Latest News

Latest News

Germany's Merck sees boost from labs supplies earnings

Germany's Merck on Wednesday said its Life Science business, a leading maker of biotech lab supplies and gear, saw core earnings jump more than 43% in the first quarter, driven by the pharma industry's efforts to fight the coronavirus pandemic.

German labs supplier Merck raises forecast on strong first quarter

German biotech labs supplier Merck raised its 2021 earnings forecast on strong first-quarter results, as efforts by the pharma industry to ready treatments and vaccines against the coronavirus bolsters demand for its products.

Congo declares end of Ebola outbreak that killed six

The Democratic Republic of Congo on Monday declared the end of an Ebola outbreak that infected 12 people in the eastern province of North Kivu and killed six of them.

Congo declares end of Ebola outbreak that killed six

The Democratic Republic of Congo on Monday declared the end of an Ebola outbreak that infected 12 people in the eastern province of North Kivu and killed six of them.

U.S. drugmaker Merck sees bigger hit to full-year sales from pandemic

Merck & Co Inc said on Thursday it would take a bigger hit to sales this year than previously expected due to a resurgence in COVID-19 cases that has hurt demand for drugs that need to be given by doctors.

BRIEF-Merck Says Not Extending Trial For COVID-19 Drug Molnupiravir Into India At This Time

* MERCK & CO EXEC SAYS Q1 VACCINE SALES HURT BY RECOMMENDATIONS AGAINST CO-ADMINISTRATION OF COVID-19 VACCINES WITH OTHER SHOTS

Merck quarterly profit falls on COVID-19 hit

Merck & Co Inc reported a 1% fall in quarterly profit on Thursday, hurt by a drop in visits to the doctor's office because of a resurgence in COVID-19 cases at the beginning of the year in the United States. (Reporting by Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila...

Merck taps five Indian drugmakers to expand COVID-19 drug production

Merck & Co Inc said on Tuesday it had partnered with five Indian generic drugmakers, including Cipla Ltd and Sun Pharmaceutical Industries Ltd, to expand production and access to its experimental COVID-19 drug.

Merck taps 5 Indian drugmakers to expand COVID-19 drug production

Merck & Co Inc said on Tuesday it had tied up with five generic drugmakers in India to expand access to molnupiravir, an experimental antiviral COVID-19 therapy it is developing with Ridgeback Biotherapeutics. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Ramakrishnan...

Merck plans large outpatient trial of COVID-19 pill, stops study in hospitalized patients

Merck & Co Inc on Thursday said it plans a large study of what could become the first pill to target the coronavirus in people at risk of severe COVID-19, but will no longer pursue use of the experimental antiviral drug in hospitalized patients.

WHO joins Europe, Merck in recommending against ivermectin for COVID-19

The World Health Organization (WHO) on Wednesday recommended against using generic anti-parasite drug ivermectin in patients with COVID-19 except for clinical trials, because of a lack of data demonstrating its benefits.

Merck names Caroline Litchfield as new CFO

Merck & Co Inc said on Wednesday Caroline Litchfield will succeed Robert Davis as the company's chief financial officer from April 1.

UPDATE 1-EU regulator warns against use of Merck's anti-parasite drug for COVID-19

Europe's drugs regulator on Monday warned against the use of Merck & Co's anti-parasite drug, ivermectin, for the treatment or prevention of COVID-19 outside clinical trials.

EU regulator advises against use of Merck's anti-parasite drug for COVID-19

The European medicines regulator on Monday advised against the use of Merck & Co's anti-parasite drug, ivermectin, for the treatment or prevention of COVID-19 outside clinical trials.

Merck's marketing executive Michael Nally to step down

Merck & Co said on Wednesday its Chief Marketing Officer Michael Nally will leave the company, the second top executive to do so after the drugmaker announced last month its Chief Executive Officer Kenneth Frazier will step down in June.

Gilead, Merck collaborate to develop long-acting HIV treatment

Gilead Sciences Inc and rival Merck & Co Inc said on Monday they will test a combination of their experimental HIV drugs to develop a long-acting treatment for the infection that affects millions worldwide.

Gilead, Merck collaborate to develop HIV treatment - WSJ

Drug makers Gilead Sciences Inc and Merck & Co Inc are collaborating to develop a long-acting HIV therapy, the Wall Street Journal reported on Monday. (Reporting By Mrinalika Roy in Bengaluru; Editing by Shounak Dasgupta)

Biden says Americans will be first to get vaccines; any surplus to be shared

The U.S. government will first give Americans COVID-19 vaccines, but any surplus would be shared with the world, President Joe Biden said on Wednesday after earlier announcing plans to procure an additional 100 million doses.

Judge shuts down MDL claiming link between diabetes drugs and pancreatic cancer

A federal judge in San Diego has rejected claims by some 1,500 plaintiffs in a multidistrict litigation that several similar type 2 diabetes drugs increase the risk of pancreatic cancer.

Idorsia insomnia drug starts FDA review as founder Clozel's second act proceeds

Idorsia's insomnia drug was accepted for review by U.S. regulators, the Swiss drugmaker said on Wednesday, as founder Jean-Paul Clozel edges closer to bringing his new company's first drug to market since selling Actelion for $30 billion.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up